Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.54 |
| ▸ | MAOB | P27338 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6586281 | 1.00 | ACHE (0.54) | ACHEMAOBALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL8724175 | 0.87 | KDM4E (0.60) | ACHEMAOBALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL8724172 | 0.87 | KDM4E (0.60) | ACHEMAOBALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL7448090 | 0.83 | ACHE (0.63) | ACHEMAOBALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL7515428 | 0.81 | ENPP1 (0.47) | ACHEMAOBCYP3A4CYP2C19 | |
| SCHEMBL7515426 | 0.81 | ENPP1 (0.47) | ACHEMAOBCYP3A4CYP2C19 | |
| SCHEMBL7661776 | 0.77 | KDM4E (0.73) | MAOBALDH1A1SMN1; SMN2KDM4ECYP1A2 | |
| SCHEMBL7661772 | 0.77 | KDM4E (0.73) | MAOBALDH1A1SMN1; SMN2KDM4ECYP1A2 | |
| SCHEMBL2528750 | 0.75 | ALDH1A1 (0.49) | MAOBALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL2528748 | 0.75 | ALDH1A1 (0.49) | MAOBALDH1A1MAPTSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1124829-B1 | TRICYCLIC PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON SPA (IT) | 2004-08-04 | — | — | EP | disclosed |
| US-20040043999-A1 | Phthalazine derivatives as phosphodiesterase 4-inhibitors | ZAMBON GROUP S.P.A | 2004-03-04 | — | — | US | disclosed |
| EP-1042300-B1 | PHTHALAZINE DERIVATIVES USEFUL AS PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON SPA (IT) | 2004-02-11 | — | — | EP | disclosed |
| US-6589951-B1 | N right-arrowO derivatives and pharmaceutically acceptable salt thereof are PDE 4 and TNF pharmaceutically acceptable salt thereof are PDE 4 and TNF alpha inhibitors. | ZAMBON GROUP S.P.A. (IT) | 2003-07-08 | — | — | US | disclosed |
| US-6525055-B1 | Allergic and inflammatory pathologies such as, for example, emphysema, chronic bronchitis, asthma and allergic rhinitis. | ZAMBON GROUP S.P.A. (IT) | 2003-02-25 | — | — | US | disclosed |
| US-6498160-B2 | FOR THERAPY OF EMPHYSEMA, CHRONIC BRONCHITIS, ASTHMA AND ALLERGIC RHINITIS | ZAMBON GROUP S.P.A. (IT) | 2002-12-24 | — | — | US | disclosed |
| US-20020058662-A1 | Phthalazine derivatives as phosphodiesterase 4 inhibitors | ZAMBON GROUP S.P.A. (IT) | 2002-05-16 | — | — | US | disclosed |
| US-6340684-B1 | TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA, ALLERGIC RHINITIS | ZAMBON GROUP S.P.A. (IT) | 2002-01-22 | — | — | US | disclosed |
| EP-1098886-A1 | PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.p.A. (IT) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000005219-A1 | PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.P.A. (IT) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058662-A1 | Phthalazine derivatives as phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | ACHE 224/4885MAOB 174/4885ALDH1A1 1029/4885 |
| US-20040043999-A1 | Phthalazine derivatives as phosphodiesterase 4-inhibitors | PDE5A, PDE3B, PDE3A | ACHE 188/4885MAOB 42/4885ALDH1A1 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.